After three decades of trial and error to target the driver of 30% of all diagnosed cancers, scientists are finally making meaningful clinical progression to target the cancer master switch, the RAS family of proteins. The RAS- Targeted Drug Discovery Summit Europe is the only industry and translational focused platform dedicated to bringing you innovative anti-RAS drug discovery science, capturing the most pioneering data, thought-provoking insights and practical lessons learned, enabling you to maximise the clinical therapeutic window of your anti-RAS candidate.
Uniting the leading minds from large pharma, biotech and academia, this summit will help you advance novel target site discovery, improve drug-like properties and accelerate the translation of potent and mutation-specific RAS targeted therapeutic strategies into human clinical trials. With numerous approaches emerging that demonstrate genuinely viable efficacy in targeting the RAS family of proteins, join the RAS- Targeted Drug Discovery Summit Europe to gain first-hand insights on the challenges and strategies to robustly translate promising anti-RAS therapies into the clinic.
Uniting the leading minds from large pharma, biotech and academia, this summit will help you advance novel target site discovery, improve drug-like properties and accelerate the translation of potent and mutation-specific RAS targeted therapeutic strategies into human clinical trials. With numerous approaches emerging that demonstrate genuinely viable efficacy in targeting the RAS family of proteins, join the RAS- Targeted Drug Discovery Summit Europe to gain first-hand insights on the challenges and strategies to robustly translate promising anti-RAS therapies into the clinic.
